Gut glucagon like peptides protect the mouse intestine from its own T cells

Gut glucagon like peptides are best known for what they do to appetite and blood sugar, but a new mouse study puts them in a different job. Working in Toronto, the laboratory of Daniel Drucker reports that gut glucagon like peptides also limit the damage done to the intestine when T cells are switched on across the whole body. Mice missing the receptors, or missing the hormones in the gut itself, were injured more. Two approved drugs that hit those receptors reduced the injury. The paper appeared in Cell Reports Medicine on 20 October 2026.

How the mice were made vulnerable

The model is blunt and well established. An antibody against part of the T cell receptor complex activates T cells throughout the animal, and the small intestine takes the hit within a day or two, losing crypts and Paneth cells and leaking more across the barrier. The team ran this anti CD3 challenge in male mice aged twelve to sixteen weeks, comparing normal animals with three engineered lines. Two lacked a single receptor each, for GLP 1 or for GLP 2. The third kept both receptors but could no longer make the shared precursor protein in the intestine, so the gut produced neither hormone locally while the brain and pancreas were unaffected.

All three lines came out worse than controls, but in different ways, which is the part of the result that carries information. Losing the GLP 1 receptor mostly worsened inflammation, with higher levels of signalling molecules that recruit neutrophils and more neutrophil marked cells in the tissue, yet without extra loss of crypts. Losing the GLP 2 receptor did the opposite, shortening villi, slowing the division of crypt cells and costing Paneth cells while inflammation stayed closer to normal. Animals with no intestinal hormone production at all had the broadest damage, including a leakier barrier, more crypt loss, a lighter small bowel and slower recovery of body weight.

What semaglutide and teduglutide did

The pharmacology arm asked whether supplying the signal from outside would help. The authors gave semaglutide, which activates the GLP 1 receptor, and teduglutide, which activates the GLP 2 receptor, separately and together, in weight based amounts kept small enough to study the receptors rather than to drive weight loss. Both reduced the damage caused by the anti CD3 antibody. Teduglutide partly restored small bowel weight relative to length, lowered intestinal signalling molecules and neutrophil infiltration and eased the appearance of the tissue under the microscope, though measures of barrier leakiness did not improve. Semaglutide lowered inflammatory markers in blood and raised the expression of genes tied to Paneth cells.

A microbiome that changes alongside tissue damage cannot be separated from the damage without further experiments, and nothing here shows that the bacteria caused the injury or the recovery.

Given together, the two drugs lowered systemic inflammatory markers, restored crypt density in the lower small intestine and reduced visible tissue damage. The authors are careful here. They do not claim that the pair beats either drug alone, because the study was not designed to answer that question and the comparison was never powered. Flow cytometry of immune cells from lymph nodes, the intestinal lining and the spleen found few shifts in the proportions of cell types after either drug, which suggests the protection came from the tissue response rather than from a change in which immune cells arrived. Semaglutide also blunted the rise in blood glucose during a sugar challenge, as expected for a drug of its class. The table sets out what each line and each treatment changed.

Why the gut makes its own GLP 1 and GLP 2

Both hormones come from the same precursor, cut differently in enteroendocrine cells scattered along the intestinal lining. GLP 1 acts on insulin release and appetite, which is why its mimics are now so widely prescribed, while the GLP 2 receptor drives growth of the lining, nutrient absorption, blood flow and barrier repair. Teduglutide is already licensed for short bowel syndrome on exactly that basis. What this paper adds is evidence that the locally made hormones, not just pharmaceutical copies, form part of the intestine's defence during an acute immune attack, since removing production in the gut alone was enough to worsen injury.

The group also sequenced bacterial DNA from faeces. T cell activation itself shifted the community, raising the share of two bacterial groups and lowering another, and this happened in normal animals as well as in those without intestinal hormone production. Diversity measures fell further in the animals lacking the hormones. The authors read this as a mostly secondary effect of the immune challenge rather than a mechanism, which is the cautious reading the data support. A microbiome that changes alongside tissue damage cannot be separated from the damage without further experiments, and nothing here shows that the bacteria caused the injury or the recovery. The sequencing is useful mainly as a check that the two genotypes were not living in different microbial worlds before the challenge began.

What a mouse study cannot settle

The limits are stated in the paper and they are real. The challenge was acute and short, the animals were young and male, and the injury was produced by an antibody rather than by the chronic inflammation that drives inflammatory bowel disease, graft versus host disease in the gut or the gut toxicity of cancer immunotherapy. Deleting the shared precursor removes more than two hormones, so other fragments cut from the same protein may have contributed to the differences. None of the measurements in this work track a human outcome, and no patient data are reported anywhere in it. The number of animals per group is modest, as it usually is in work of this kind.

There is also a practical gap between the model and any use in people. Gut glucagon like peptides were supplied here at amounts chosen for receptor biology, while the doses used clinically for weight loss are aimed at a different target and bring appetite suppression with them. Whether a receptor agonist could calm immune driven gut injury in a person without unwanted weight loss is exactly the question the authors propose for future work. Until a trial in people asks it, this remains a mechanism paper about mice, useful for designing the next experiment rather than for treating anyone now.

Conclusion

Gut glucagon like peptides look less like appetite hormones and more like part of the intestinal repair kit in this work. Removing either receptor made mice worse after T cell activation, removing local production made them worse still, and two licensed receptor agonists reduced the injury. The findings come from a short, sharp model in young male mice, and they say nothing yet about patients. The useful next step is a slower model of chronic immune injury and, eventually, a trial.

Source Koehler JA and colleagues. Gut-derived glucagon-like peptides attenuate T cell-induced intestinal injury. Cell Reports Medicine, published 20 October 2026. DOI 10.1016/j.xcrm.2026.103115

Amino Weekly reports research. It is not medical advice and never gives doses.